Sang­amo puts down $84M to ac­quire Tx­Cell, div­ing in­to CAR-Treg space, au­toim­mune dis­eases

7 years ago
Deals

Hu­man Longevi­ty blasts Craig Ven­ter, claim­ing he was fired, then stole trade se­crets — poach­ing staffers for ri­val ...

7 years ago
People

Num­ber 7? Cel­gene part­ner BeiGene joins the crowd with stel­lar PD-1/L1 da­ta from a piv­otal test

7 years ago
R&D

Fed­er­al judges ban Al­ler­gan’s sov­er­eign im­mu­ni­ty scheme in a slap­down that will bol­ster in­ter partes re­view for ...

7 years ago
Bioregnum
Opinion

Agios scores its sec­ond new drug ap­proval, ivosi­denib heads to the AML mar­ket

7 years ago
Pharma

An­tho­ny Quinn ce­ments Ae­glea CEO spot; Hu­man Longevi­ty bumps David Karow up to the top

7 years ago
Peer Review

BMS part­ners with Grit­stone on sol­id tu­mor com­bos; Roche's Alzheimer's di­ag­nos­tic gets break­through sta­tus

7 years ago
News Briefing

Bat­tered and weary, Vi­cal flags for help fol­low­ing its line­up of lemons

7 years ago
R&D

So­bi signs $450M deal for rare dis­ease drug ema­palum­ab, boost­ing its in­flam­ma­tion, I/O pipeline

7 years ago
Pharma

Roche has tak­en the Trump pledge, join­ing Pfiz­er, No­var­tis and Mer­ck in promis­ing to hold the line on drug prices

7 years ago
Pharma

This week’s Nas­daq casi­no win­nings: About $700M for 6 biotech IPOs as shares start mov­ing north

7 years ago
Financing

PureTech grabs up to $36M from Roche to re­search milk-in­spired de­liv­ery plat­form

7 years ago
Pharma

Nab­bing late-stage drug, PTC ac­quires gene ther­a­py start­up Ag­ilis for $200M in cash/stock

7 years ago
Deals

In an­oth­er win for Trump, Mer­ck takes the drug pric­ing pledge. Its cuts are a joke, but is this an in­dus­try tip­ping ...

7 years ago
Pharma

FDA’s CDER un­veils de­tails of re­or­ga­ni­za­tion

7 years ago
Pharma

Ipsen adds cowork­ing to new Boston HQ with Bi­o­Labs part­ner­ship; NYC gets biotech start­up ac­cel­er­a­tor, fund­ed with ...

7 years ago
News Briefing

Post-Bris­tol/My­ers buy­out, the IFM team lines up $31M to tack­le a troi­ka of NL­RP3 tar­gets

7 years ago
Financing

In two PhI­II wins for Al­ler­gan/Mol­e­c­u­lar Part­ners, wet AMD drug shows non-in­fe­ri­or­i­ty to Lu­cen­tis

7 years ago
R&D

Aridis Phar­ma seeks $35M to fight in­fec­tions with im­munother­a­pies — lat­est in an IPO streak

7 years ago
Financing

The Shkre­li rule? FDA is ex­plor­ing whether se­lect­ed reim­por­ta­tion could crip­ple the drug prof­i­teers

7 years ago
Pharma

Af­ter bil­lion-dol­lar drug deal, pa­tient death and tri­al hold crip­ple Mer­sana's shares

7 years ago
R&D

Gilead brings Medicxi’s tiny Gade­ta in­to the cell ther­a­py fold, hunt­ing a way to pick the lock on sol­id tu­mors

7 years ago
R&D
Discovery

Go­ing deep­er in­to the ezce­ma game, No­var­tis or­ches­trates $1.1B deal for a Mor­phoSys/Gala­pa­gos drug

7 years ago
R&D
Pharma

Roche’s IM­pow­er 132 hits on pro­gres­sion-free sur­vival, but Mer­ck re­mains in con­trol — for now — on front­line ...

7 years ago
R&D
First page Previous page 1024102510261027102810291030 Next page Last page
A service from the Financial Times